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Toxicology of Di-2-ethylhexyl Phthalate
and Other Phthalic Acid Ester
Plasticizers
by Robert M. Gesler* t
The first poly(vinyl chloride) blood bag
containing di-2-ethylhexyl phthalate (DEHP)
as a plasticizer was introduced in medicine
in 1950. Since then, millions of liters of
blood collected in plastic have been trans-
fused. Aside from the obvious advantages of
plastic over glass containers for the collec-
tion, storage and transfusion of blood,
plastic containers have made blood compo-
nent therapy possible; at least six different
blood fractions can now be separated asep-
tically from whole blood and administered
individually to the patient as needed.
Poly(vinyl chloride) plastics containing
DEHP also have been employed in a variety
of other biomedical devices, including trans-
fusion and infusion assemblies, administra-
tion sets, artificial kidney connecting tubing,
bubble-type oxygenators, catheters, enema
and urinary drainage bags, etc. Plasticized
poly(vinyl chloride) plastics were selected
for these medical applications principally be-
cause of their unique physical properties, ease
of fabrication, low cost, and apparent safety.
To provide the necessary flexibility, relative-
ly high levels of plasticizer (up to 40%) must
be blended into the plastic formulation.
Recent reports have identified milligram-%
quantities of DEHP in blood or plasma
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stored in poly(vinyl chloride) blood bags
(1-3) and microgram per gram amounts in
certain tissues of recipients (3, 4). These
findings have raised questions of possible
hazard for man exposed to such levels of
plasticizer.
This paper is a review of the available
toxicologic data on DEHP and other
phthalate plasticizers to determine: (1) the
current status of the toxicologic information
on these materials, and (2) the types of




Because the phthalate esters as a group
and DEHP in particular are viscous oils with
poor water solubility, it is not possible to
determine an intravenous median lethal dose
(LD50) for these compounds. However, sev-
eral laboratory groups have determined acute
toxicity by other routes of administration
on a number of phthalate esters. These data
are summarized in Table 1.
It is evident as noted by many investi-
gators that the shorter chain phthalate esters
are more toxic than the longer chain com-
pounds. A wide range of LD50 values has
been reported for DEHP. To what extent
this variation in toxicity may reflect variable
contamination with free phthalic acid [intra-
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Phthalate Animal Route of LD50, Reference
ester species administration a g/kg
Dimethyl Mouse IP <0.97-2.86 (5-7)
Diethyl Mouse IP <1.11-2.83 (6,7)
Di-n-propyl Mouse IP <1.25 (7)
Diisopropyl Mouse IP <1.25 (7)
Di-n-butyl Mouse IP <1.39-5.76 (5-7)
IM >8 (8)
PO ca. 8 (8)
Rat PO 23.0 (9)
Diisobutyl Mouse IP 4.5 (6)
Di-n-hexyl Rat PO 29.6 (10)
Di-2-ethylhexyl Mouse IP 14.19->128 (6,11,12)
Rat IP >23.8->70 (12-14)
PO 30.6->60 (12-14)
Rabbit IP >31 (13)
PO 33.9 (14)
Dialkyl (79) Mouse IP >20 (15)
PO >20 (15)
Rat IP >20 (15)
PO >20 (15)
Di-n-capryl Mouse IP 14.19 (6)
a IP = intraperitoneal; IM = intramuscular; PO = by mouth.
peritoneal LD50 = 0.55 g/kg (5)] or other
impurities is not known. The DEHP evalu-
ated in our laboratory (11) had an intra-
peritoneal LD50 in mice of greater than 75
g/kg and was more than 99% pure as deter-
mined by gas chromatography and contained
less than 0.01% free phthalic acid.
In any event, DEHP administered either
orally or intraperitoneally has a low order of
toxicity. The magnitude of the LD50 values
by these routes of administration (as high as
10% of body weight) likely indicates a non-
specific type of toxicity, possibly the result
of impurities or of local effects of the oily
compound within the gastrointestinal tract
or peritoneal cavity. Unabsorbed DEHP can
be recovered in appreciable quantities from
the peritoneum for at least 3 days after
intraperitoneal injection. Absorption of
DEHP into the systemic circulation from
such injection sites therefore is quite limited.
Quantitative studies of its rate of transfer
across biologic membranes have not been
reported.
Effects on CeUls in Tissue Culture
One of the most sensitive measures of
biocompatability is the tissue culture assay,
first applied to the evaluation of plastics and
plastic ingredients by Guess and co-workers
(16). A number of phthalate esters since have
been tested for toxic effects on tissue cul-
ture cells. These data are summarized in
Table 2.
Bioincompatability of the phthalates in
these isolated cell systems is seen with the
lower chain dialkyl esters, which also have
greater water solubility than the higher chain
homologs. Dillingham and Autian in this
symposium (19) have reported that the
dose-cytotoxicity response curves for four
lower-chain dialkyl esters is limited, not un-
expectedly, by solubility. Probably because
of its low aqueous solubility, DEHP has not
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Effects on tissue cultures a
Phthalate Mouse fibroblast L-cells 10-Day chick embryo cells Reference
ester Pure ester SSS b Emulsion c Pure ester SSS b Emulsion c
Dimethyl + - + + - - (6,7,1 7)
Diethyl +,- - + +,- - - (6,7,17)
Di-n-propyl + NT NT + NT NT (7)
Diisopropyl + NT NT + NT NT (7)
Di-n-butyl + NT - + NT - (6,7)
Diisobutyl + - - + - - (6,7,17)
Di-n-pentyl + NT NT - NT NT (7)
Di-n-hexyl - NT NT - NT NT (7)
Di-2-ethylhexyl - NT - NT NT - (6,18)
Di-n-octyl - - NT - - NT (7,17)
Di-n-capryl - - - - - - (6,17)
a Symbols: +, cell death; -, no cell toxicity; ±, equivocal results; NT, not tested.
b Saturated saline solution of ester.
c 0.05 ml of 50 mg/ml emulsion of ester.
been demonstrated to be cytotoxic in any of
these cell culture systems.
Human blood stored in anticoagulant-
nutrient solution, however, is a tissue culture
system which contains significant quantities
of lipophilic substances. Extensive experi-
ence has now been accumulated on the use
of banked blood stored for up to 21 days in
flexible bags made of poly(vinyl chloride)
with DEHP plasticizer.
Tests on plastic blood collection units pre-
pared from 24 consecutive batches of plastic
showed that in vivo red blood cell survival in
man averaged 82% with a standard deviation
of 6.2% for blood stored 21 to 23 days at
40C (20). Red cell survival was greater than
the National Institutes of Health minimum
permissable level of 70% in 96% of such
tests, although up to 11.5 mg-% of DEHP
has been shown to accumulate in blood
stored in plasticized poly(vinyl chloride)
blood bags for 21 days (1).
Miscellaneous Effects
The phthalate esters have been evaluated
also for both local and systemic "subtle"
pharmacologic and toxicologic effects in a
number of other biologic systems. These
studies include intradermal irritancy (6),
effects on the electroencephalogram, blood
pressure, and respiration (6), effects on hex-
obarbital sleeping time (6, 21) and on zoxa-
zolamine paralysis time (21), interaction
effects of phthalates and antibody (22),
effects on conditioned behavior, reticulo-
endothelial function, and on aggregates of
microemboli in stored blood (21).
The validity of these results implying
specific pharmacologic or toxicologic actions
of DEHP however needs to be given careful
scrutiny. In most of these studies large doses
much in excess of the solubility limit of
DEHP were used to demonstrate effects,
necessitating administration of DEHP in a
nonphysiologic dosage form as an oil emul-
sion. In no case were non-DEHP emulsions
included as controls to establish the
nonspecific effects of the emulsions them-
selves. Further, responses to only a single or
at most two dose levels were determined so
that a complete dose-response curve over a
broad dosage range was not established.
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Jaeger (21), DEHP has not been demon-
strated to produce any effects in any of
these systems at dosages or concentrations
that could be completely solubilized and
which therefore necessarily would represent
true pharmacologic actions. The micro-
aggregate system studied by Jaeger is com-
plex, and though he found an apparent
increase in micro-aggregate formation in
blood stored in poly(vinyl chloride) plastic,
his experiments did not exclude other possi-
ble causes for this effect. In the absence of
conclusive data obtained from more critical
experimentation demonstrating specific phar-
macologic responses to DEHP, it is prema-
ture to conclude that such effects of DEHP
have been well established.
Chronic Toxicity
Only a few of the phthalate esters have
been evaluated in long term toxicity studies
and these have been done by the oral route
of administration only. Ninety-day oral
studies of dialkyl 79 phthalate, a widely
used plasticizer in the United Kingdom, have
been conducted by Gaunt et al. (15). A
"no-effect" dietary level was determined to
be 0.125%, equivalent to a daily dose of
approximately 60 mg/kg (see Table 3).
Dibutyl phthalate, along with some non-
phthalate plasticizers, was studied by Smith
(8) in a 1 yr rat study. A dietary level of
1.25% killed five of ten animals during the
first week, but the survivors at this level and
all animals at the next lower level of 0.25%
Table 3. Summary of chronic toxicity data on phthalate esters.
Number of Study No-effect level
Phthalate Animal animals in study duration,
ester species Controls RX weeks % in diet Mg/kg/day Toxic signs ^ Reference




Di-n-butyl Rat 10 40 52 0.25 110-330 Death at 1.25% (8)








86 172 to 104 0.1 40-80 Same (13)
Guinea pig 46 93 52 0.13 60 Increased liver (23)
weight in fe-
males only











a At higher than no-effect level.
b Number not given but "appropriate controls" were included in the study.
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showed no signs of clinical or tissue toxicity
(Table 3).
DEHP has been the subject of more in-
vestigations of long term toxicity than any
other phthalate ester. Oral studies lasting
from 90 days to 2 years in the rat, 1 year in
the guinea pig, and up to 1 year in the dog
have been conducted at several different
laboratories (13, 14, 23). These investiga-
tions have established a "no-effect" oral
dose of about 60 mg/kg/day. Higher dosages
were associated with growth retardation and
increased liver and kidney weights in rats.
No microscopic abnormalities attributable to
DEHP were noted. The dog studies to date
have not challenged a large enough group of
animals to characterize adequately the clinic-
al and tissue toxicity of DEHP at toxic
doses in this species. The study conducted
by Carpenter et al. (23) showed that a dose
of 0.06 ml/kg administered five times a
week for 1 yr produced no apparent clinical
toxicity or gross or microscopic pathology
of the major organs, except for one animal
that did show slight tubular degeneration of
the kidney. This latter change had a ques-
tionable relationship to DEHP ad-
ministration.
Carpenter et al. (23) also studied the ef-
fects of DEHP on reproductive performance
of both male and female rats and on survival
and histopathology of first-generation off-
spring. More specific teratologic studies of
DEHP and other phthalates have been con-
ducted by McLaughlin et al. (24) Guess et
al. (22), Bower and co-workers (25), and by
Singh, Lawrence, and Autian (26). These
studies will be the subject of the next pre-
sentation in this symposium (19).
Discussion
DEHP has been evaluated more extensive-
ly for toxicity than any other phthalate
plasticizer in general use. Although not rele-
vant to the subject of this paper, it should
be noted also that there are no non-
phthalate plasticizers that have been studied
any more carefully. Yet, admittedly, our
present understanding of the pharmacology
and toxicology of DEHP is incomplete. We
know little about its toxicity following re-
peated exposure by parenteral routes of
administration which must be considered for
most biomedical uses of plastics. Moreover,
cognizance of the special problems of sol-
ubilizing this material to provide a dosage
form for administration that mimics the way
in which man is exposed is necessary to
determine its clinically relevant pharma-
cologic and toxicologic actions.
DEHP has been identified in tissues of
humans exposed to biomedical plastics (4),
but the relationship between biomedical ex-
posure versus environmental or other modes
of exposure to plasticizers and DEHP tissue
levels has not been studied systematically.
Further, the ultimate fate of tissue bound
DEHP as well as the kinetics of its distribu-
tion between tissue and vascular compart-
ments is unknown.
The presence of DEHP in the human
body has prompted speculation of possible
deleterious effects. While it is clear that
DEHP in human tissue cannot be considered
beneficial, it should be noted and em-
phasized in this symposium that there is no
clear evidence that an adverse cause-and-
effect relationship does in fact exist. As a
representative of industry that manufactures
blood bags and other biomedical devices
made from plasticized plastics, we recognize
our responsibility to take the initiative in
completing the safety evaluation of DEHP.
The four principal manufacturers of blood
bags (Abbott, Baxter, Cutter, and McGaw
Laboratories) are collaborating in this effort
and have contracted the Stanford Research
Institute to carry out animal studies de-
signed to determine (1) the extent of oral
absorption of DEHP as an intact diester, (2)
tissue distribution of DEHP following intra-
venous administration, and (3) half-life of
DEHP in blood and tissues and time to zero
residue. Obviously, if significant oral absorp-
tion of DEHP occurs, its parenteral toxi-
cology can be considered to be basically
similar to its oral toxicology about which we
have extensive data. On the other hand, if
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parenteral toxicity studies need to be under-
taken. Preliminary findings from the collab-
orative study indicate that there is
significant absorption of DEHP from the gas-
trointestinal tract.
The determination of decay rates of
DEHP levels in blood and tissues will place
the significance of the finding of DEHP in
human tissues in better perspective. In this
connection, medical departments of the in-
dustry group in collaboration with the labor-
atories of Dr. Robert Rubin, Johns Hopkins
University, and Dr. Padmanabhan Nair, Sinai
Hospital, Baltimore, are conducting a study
in man to establish the relationship between
exposure to plasticized plastics and tissue
levels of DEHP.
Finally, I want to caution this symposium
that we not lose sight of the risk-to-benefit
ratio in our efforts to study and define the
risk associated with biomedical exposure to
plasticizers. Some forms of life-saving
therapy would not be possible presently
without DEHP-plasticized plastics.
Summary
* DEHP and other phthalate esters have
been tested for acute toxicity primarily
in mice and rats and tissue culture cells.
The lowerchain dialkyl esters are more
toxic in these systems than their longer
chain homologs.
* DEHP and other plasticizers have been
assessed for "subtle" toxicity in a num-
ber of other biologic systems. The
methodologic limitations of these evalu-
ations are pointed out.
* Chronic toxicity data are available on
DEHP which have established an oral
"no-effect" dose of about 60 mg/kg/
day for a period of one year. Chronic
toxicity studies of DEHP administered
by a parenteral route are not available.
* The manufacturers of plasticized blood
bags are supporting a study presently
being conducted at Stanford Research
Institute to determine oral absorption,
tissue distribution, and tissue half-life
of DEHP. In addition a study of human
tissue is in progress to define the rela-
tionship between exposure to biomed-
ical plastics and DEHP tissue levels.
0 Concern over risk of exposure to DEHP
plasticized plastics needs to be kept in
proper perspective, inasmuch as many
biomedical devices incorporating such
plastic provide therapeutic benefit often
life-saving.
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